January 16, 2025
MINNEAPOLIS, MN — January 10, 2025 (PR Newswire) Saluda Medical, Inc., a commercial-stage medical device company focused on development treatments for chronic neurological conditions using a novel closed-loop, dose-control neuromodulation platform, today announced the closing of a $100 million financing. FLG Managing Partner Laureen DeBuono assisted as Board of Directors Member and Audit Committee Chair.
Read the full press release.